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SUMMARY
The dopamine (DA) D2 receptor (D2R) is an important target for the treatment of neuropsychiatric 
disorders such as schizophrenia and Parkinson’s disease. However, the development of improved 
therapeutic strategies has been hampered by our incomplete understanding of this receptor’s 
downstream signaling processes in vivo and how these relate to the desired and undesired effects 
of drugs. D2R is a G protein-coupled receptor (GPCR) that activates G proteindependent as well 
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as non-canonical arrestin-dependent signaling pathways. Whether these effector pathways act 
alone or in concert to facilitate specific D2R-dependent behaviors is unclear. Here, we report on 
the development of a D2R mutant that recruits arrestin but is devoid of G protein activity. When 
expressed virally in “indirect pathway” medium spiny neurons (iMSNs) in the ventral striatum of 
D2R knockout mice, this mutant restored basal locomotor activity and cocaine-induced locomotor 
activity in a manner indistinguishable from wildtype D2R, indicating that arrestin recruitment can 
drive locomotion in the absence of D2R-mediated G protein signaling. In contrast, incentive 
motivation was enhanced only by wildtype D2R, signifying a dissociation in the mechanisms that 
underlie distinct D2R-dependent behaviors, and opening the door to more targeted therapeutics.
Introduction
The neuromodulator dopamine (DA) plays major roles in motor function, motivation, 
rewardlearning, and cognition1–3, and its dysregulation has been implicated in psychiatric 
and neurological disorders including schizophrenia4, Parkinson’s disease5, addiction6, 
ADHD7, obsessive compulsive disorder8, and Tourette’s syndrome9. DA confers its actions 
through five seven-transmembrane, G protein-coupled receptors (GPCRs) (DARs; D1-D5R) 
that are distributed heterogeneously throughout the central nervous system. D2R is notable 
for its clinical importance as a therapeutic target. D2R is blocked by all current antipsychotic 
medications10, 11, is activated by anti-Parkinsonian medications12, and has been implicated 
as a target for the treatment of addiction13. However, medications that target this receptor 
have numerous on- and off-target effects that impair quality of life and medication 
compliance. Furthermore, the precise D2R localization and downstream intracellular signal 
transduction mechanisms that must be targeted to bestow clinical efficacy remain unknown.
Elucidating the roles of D2R in living animals is challenging in part because it is expressed 
heterogeneously across diverse cell types and brain regions14. For example, D2R is highly 
enriched in the striatum15, where it is expressed in functionally distinct neurons including 
the “indirect pathway” medium spiny projection neurons (iMSNs) as well as cholinergic 
interneurons (ChIs)14, 16. D2Rs also act as auto- and heteroreceptors at the terminals of 
dopaminergic midbrain17 and glutamatergic cortical neurons18, respectively, that innervate 
the striatum. Postand pre-synaptic striatal D2Rs are thought to play distinct roles, with the 
former regulating somato/dendritic excitability19 and the latter regulating transmitter 
synthesis and release20.
D2R can engage a multitude of signaling pathways within the same cell. D2R couples to 
Gi/o/z proteins15, which inhibit adenylyl cyclase to decrease cAMP levels, and also regulate 
signaling proteins such as DARPP-3221, ion channels22–26, and transcription factors27. D2R 
also recruits arrestins (arrestin-2 and −3)28, 29, which terminate G protein signaling, facilitate 
receptor internalization, and engage non-canonical, G protein-independent signaling 
pathways30. Whether G protein- and arrestin-dependent pathways act alone or in concert to 
facilitate specific D2R-dependent processes is not well understood.
Traditional pharmacological agents, i.e., agonists and antagonists of D2R, have two 
limitations. First, they target receptors in a cell type-independent manner and therefore it is 
difficult to identify their site of action, especially within the striatum. Second, they are 
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largely pathway-independent so it is unclear which signaling pathway is responsible for an 
observed behavioral effect. Recently, novel ligands have been developed that are 
functionally selective, or biased, in their ability to activate either G proteins or arrestins 
downstream of D2R31–34. Though promising, these ligands are often partial agonists 
compared to DA and only have limited bias. Moreover, biased ligands cannot overcome the 
cell type specificity limitation, and like classical ligands, have off-target effects at other 
DARs and other targets. While the genetic knockout of specific signaling proteins can 
partially address these limitations35, 36, this approach is not specific to D2R signaling and is 
complicated by potential compensation during development.
Limitations associated with existing pathway-selective approaches are highlighted by studies 
investigating the role of arrestin signaling on D2R-dependent locomotion. Biased ligands 
that preferentially engage arrestins downstream of D2R were shown to inhibit DA-
dependent, psychostimulant-induced locomotion in mice, suggesting that arrestin signaling 
inhibits locomotion31. However, the global knockout of arrestin-3 attenuated 
psychostimulant-induced locomotion, suggesting that arrestins are necessary for 
locomotion35. This discrepancy is likely due to the partial agonism of the biased compounds 
as well as the potential multitude of on- and off-target effects associated with these 
approaches.
We recently showed that upregulating D2R in iMSNs of the nucleus accumbens (NAc-
iMSNs) of adult mice enhances both locomotion and motivation in mice37, 38. These 
overexpressed receptors are activated by endogenous DA, thereby obviating the need for 
exogenous ligands and maintaining the spatio-temporal aspects of signaling. Here, we 
further refined this approach to study, with cell type specificity, the precise role of arrestin 
recruitment to D2R and its presumed downstream signaling effects. We developed an 
arrestin-specific biased mutant of D2R by disrupting the receptor’s ability to activate G 
proteins. Virus-mediated expression of this mutant in NAc-iMSNs within a D2R-knockout 
background was sufficient to reverse blunted basal locomotor activity in these animals as 
well as to restore the locomotor response to cocaine to levels identical to that achieved by 
wildtype D2R. Remarkably, in contrast to wildtype, the expression of this mutant in NAc-
iMSNs enhanced locomotion but not motivation, indicating that these behaviors are 
differentially regulated by D2R-mediated arrestin recruitment and that enhancing motivation 
requires G protein activation.
Materials and Methods
Modeling
The molecular representation of D2R co-crystalized with the antagonist risperidone (pdb: 
6CM4)39 was prepared using Chimera, which was developed by the Resource for 
Biocomputing, Visualization, and Informatics at the University of California, San Francisco 
(supported by NIGMS P41-GM103311).
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Molecular biology and heterologous expression
The short or long isoforms of human D2R were cloned into the expression vector pcDNA3.1 
with a signal peptide to enhance receptor expression, a FLAG-tag at the receptor N-
terminus, and with or without Renilla luciferase 8 (Rluc8) at the receptor C-terminus40. 
Point mutations in D2R were introduced using the QuikChange site-directed mutagenesis 
method (Stratagene, La Jolla, CA) per the manufacturer’s instructions. For the 
bioluminescence resonance energy transfer (BRET)- based assays used in this study, 
HEK293T cells were seeded onto 10 cm plates and transfected with a 1:1 ratio of 
DNA:polyethylenimine (linear, MW 25,000; PolySciences, Inc.). For the BRETbased D2R-
mediated Gi1 recruitment assay, we transfected plasmids encoding D2R-Rluc8 (0.2 μg), 
human Gαi1 with mVenus inserted at position 91 (Gαi1–91-mVenus; 5 μg) and human Gβ1 
and human Gγ2 (5 μg each). For the BRET-based D2R-mediated Gγ-mVenus recruitment 
assay, HEK293T cells were seeded onto 6-well plates and transfected with a 1:6 ratio of 
DNA:polyethylenimine with plasmids encoding D2R-Rluc8 (50 ng), the pertussis toxin 
insensitive variants (cDNA resource center, Bloomsburg University, PA, 50–125 ng) of 
human Gαi1 C351I, Gαi2 C352I, Gαi3 C351I, GαoA C351I, or WT human Gαz, human Gβ1 
(125–250ng) and human Gγ2- mVenus (125–250 ng). For the D2R-mediated arrestin 
recruitment assay, we transfected D2RRluc8 (0.2 μg), bovine GRK2 (5 μg) and bovine 
arrestin-2 or human arrestin-3 fused to mVenus at their N-termini (8 μg)41, 42. For the D2R-
AP2 interaction assay, we transfected D2R-Rluc8 (0.2 μg), arrestin-3 (5 μg), GRK2 (5 μg) 
and β2-adaptin subunit of AP-2 fused to YFP43 (10 μg). For the BRET-based D2R-mediated 
cAMP inhibition assay, we transfected plasmids encoding D2R (0.2 μg) and CAMYEL44 (6 
μg; ATCC). For cAMP inhibition experiments in which Gi1 was overexpressed, HEK293T 
cells were seeded onto 6-well plates and transfected with CAMYEL (1 μg), D2R-WT or its 
mutants (0.06 μg), Gαi1 (0.165 μg), Gβ1 (0.5 μg) and Gγ2 (0.5 μg), For measuring receptor 
surface expression as well as internalization, D2R-WT and its mutants were cloned into 
pcDNA5/FRT/TO with a signal peptide and FLAG-tag at the receptor N-terminus. These 
plasmids were stably transfected into Flp-in T-Rex HEK293 cells using the Flp-in system 
(Thermo Fisher). Stable cell lines were seeded onto 10 cm plates 48 hours prior to the assay. 
Receptor expression was induced with 1 μg/mL tetracycline 24 hours prior to the assay. For 
the internalization assay, cells were also transiently transfected with pcDNA3.1 plasmids 
encoding arrestin-3 and GRK2 using a 1:1 ratio of DNA:polyethylenimine 24 hours prior to 
the assay.
HEK293T cells used in this study tested negative for mycoplasma contamination.
Bioluminescence resonance energy transfer (BRET) assays
All BRET studies were performed in HEK293T cells that were maintained in DMEM 
(Invitrogen) with 10% fetal bovine serum at 37 °C under 5% CO2. Cells were transiently 
transfected with the plasmids described above. Cells were prepared and assayed as described 
previously in detail42. Briefly, cells were washed, harvested and resuspended in DPBS 
containing 5 mM glucose at room temperature. Cells (~40 μg of protein per well according 
to a BCA protein assay kit, ThermoScientific) were distributed into a 96-well microplate 
(Wallac, PerkinElmer Life and Analytical Sciences). After incubation with coelenterazine H 
(5 μM) (Dalton Pharma Services) for 8 minutes, different ligands were injected and 
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incubated for 2 to 10 minutes. For the CAMYEL assay, 30 μΜ of forskolin was added 10 
minutes prior to the injection of DA. For the Gγ-mVenus recruitment assay, cells were 
harvested from 6-well plates 24 hours after transfection and plated into poly-D-lysine coated 
(Sigma-Aldrich) white-bottom 96-well optiplates (Wallac, PerkinElmer Life and Analytical 
Sciences) at a density of 50,000 cells per well. Cells were treated with 100 ng/mL pertussis 
toxin (Sigma-Aldrich) 16 hours prior to assay measurement. Twenty four hours after cells 
were transferred to plates, media was aspirated, cells washed once with DPBS and 80 μL 
DPBS containing 5 mM glucose was added to each well. Using a Pherastar FS plate reader 
(BMG Labtech), BRET1 signal was determined by quantifying and calculating the ratio of 
the light emitted by mVenus (510–540 nm) over that emitted by Rluc8 (485 nm).
Receptor surface expression and internalization
To measure surface expression of D2R-WT or its mutants, live cells were washed, harvested 
and resuspended in DPBS. For the internalization assay, live cells were preincubated with or 
without 10 μM DA for one hour at 37 °C under 5% CO2, and then washed, harvested and 
resuspended in DPBS. Cells were then incubated with mouse anti-FLAG M2 antibody 
(1:400 dilution; Sigma) for 30 minutes on ice, washed and resuspended in DPBS. Cells were 
then incubated with goat antimouse lgG(H+L)-Alexa 647 antibody (Thermo Fisher) for 30 
minutes on ice, washed and resuspended in DPBS. Receptor expression was assessed using a 
BD Accuri C6 cytometer.
Animal
For D2R overexpression in wild-type mice we used adult hemizygous male and female D2-
Cre (ER44; GENSAT, backcrossed for over 5 generations onto C57BL/6J background). For 
reexpression of D2Rs in indirect pathway of D2R KO mice, A2A-Cre(KG126;GENSAT) 
were crossed with Drd2−/−mice (B.6129S2-Drd2tm1low strain backcrossed for 20 generations 
onto C57BL/6J background45). Drd2−/+A2A-Cre (homozygous for A2A-Cre transgene) 
mice were intercrossed to obtain Drd2−/−A2A-Cre (hemizygous for A2A-Cre transgene). 
Mice were housed 3–5 per cage for most experiments on a 12 hour light/dark cycle. All 
experiments were conducted in the light cycle. All experimental procedures were conducted 
following NIH guidelines and were approved by Institutional Animal Care and Use 
Committees of Columbia University, New York State Psychiatric Institute, and the VA 
Portland Health Care System.
D2-Cre+/− or Drd2−/−A2A-Cre+/− mice (≥ 8 weeks old) were bilaterally injected with a 
Credependent double-inverted open reading frame (DIO) adeno-associated viruses (AAVs) 
encoding the long isoform of D2R-WT36, 37 or the arrrestin-biased mutant (D2R-ARB) 
followed by IRESmVenus, or a DIO AAV encoding EGFP (UNC Vector Core, Chapel Hill, 
NC) into the nucleus accumbens (NAc) using stereotactic Bregma-based coordinates: AP, 
+1.70 mm; ML, ±1.20 mm; DV, −4.1 mm (from dura) for behavioral experiments. For the ex 
vivo GTPγS incorporation assay, mice were injected bilaterally at two different coordinates 
in the dorsal striatum instead of the NAc to increase striatal tissue yield (AP, +1.3 mm; ML, 
+/−1.4 mm; DV, −3.3 mm, and AP, +0.9; ML, +/− 2.0; DV, −3.4 mm from dura). Groups of 
mice used for experiments were first assigned their AAVgenotype in a counterbalanced 
fashion that accounted for sex, age and home cage origin.
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Histology
Mice were transcardially perfused with ice-cold 4% paraformaldehyde (Sigma, St. Louis, 
MO) in PBS under deep anesthesia. Brains were harvested, post-fixed overnight and washed 
in PBS. Free-floating 30-μm coronal sections were obtained using a Leica VT2000 
vibratome (Richmond, VA). After incubation in blocking solution (10% fetal bovine serum, 
0.5% bovine serum albumin in 0.5% TBS-Triton X-100) for 1 hour at room temperature, 
sections were labeled overnight at 4°C with primary antibodies against GFP/mVenus 
(chicken; 1:1000; AB13970 Abcam, Cambridge, MA) and D2R (rabbit; 1:500; in-house). 
Sections were incubated with fluorescent secondary antibodies (donkey anti-chicken FITC, 
1:400; 703–096-155; Jackson ImmunoResearch, West Grove, PA and donkey anti-rabbit 
Alexa 546; 1:400; A10040; Invitrogen, Carlsbad, CA)for 2 hours at room temperature. 
Sections were then mounted on slides and coverslipped with Vectashield containing DAPI 
(Vector, Burlingame, CA). Digital images were acquired using a Nikon epifluorescence 
microscope, and processed with NIH Image J software. For D2R fluorescence intensity 
analysis, NIH Image J software was used to draw an ROI outlining the regions of the NAc 
with virus-induced D2R expression in each section, and mean intensity values were 
calculated. These values were normalized to background fluorescence in an adjacent 
unlabeled region (medial septum) for Drd2−/−A2A-Cre or to endogenous D2R 
immunofluorescence in striatum for D2-Cre mice. Values were obtained from individual 
hemispheres and used as individual data points for analysis.
Ex vivo GTPγS incorporation assay
Four weeks after surgery, brains were harvested into ice-cold PBS promptly following 
decapitation. Striatal tissue was dissected from each hemisphere on ice and then snap frozen 
in liquid nitrogen and stored at −80°C and shipped overnight on dry ice to Jupiter, FL where 
experimenters were blinded as to treatment groups. G protein-coupling in mouse brain was 
measured using a previously published protocol46,47. Membranes were prepared following 
glasson-glass dounce homogenization in homogenization buffer (10 mM Tris-HCl, pH 7.4, 
100 mM NaCI, 1 mM EDTA, 1 mM DTT). The homogenate was passed through a 26-gauge 
needle, centrifuged twice at 20,000 × g for 30 min at 4 °C, and resuspended in ice-cold assay 
buffer (50 mM Tris-HCI pH 7.4, 100 mM NaCI, 5 mM MgCl2, 1 mM EDTA, 1 mM DTT 
and 2 μΜ GDP for CB1 activation and 100 μM GDP for D2 activation). In a 96-well plate 
format, 2.5 μg of membrane protein was incubated in assay buffer containing ~0.1 nM 
[35S]GTPγS and increasing concentrations of test compound in a total volume of 200 μL for 
1 h at room temperature. Test compounds (quinpirole or CP-55940) added to the assays at 
final DMSO concentration of 1%. Reactions were terminated by filtering through GF/B 
filters using a plate harvester (Brandel Inc., Gaithersburg, MD) and rinsing with cold dH2O. 
Filters were dried overnight, and radioactivity was determined with a microplate scintillation 
counter. The average of n=3 individual mouse striatum preparations were performed in 
duplicate presented as mean ± S. E. M.
Open field locomotor activity
Basal locomotion was assessed in open field boxes equipped with infrared photobeams to 
measure locomotor activity (Med Associates, St. Albans, VT) over 90 minute sessions. Data, 
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expressed as distance traveled, were acquired using Kinder Scientific Motor Monitor 
software (Poway, CA). Cocaine-stimulated activity was measured in activity monitors (40 
cm2; Accuscan Instruments, Inc., Columbus, OH), with 15 mg/kg of the drug injected i.p. 
after 90 minutes of acclimation to the chambers.
Operant apparatus
Eight operant chambers (model Env-307w; Med-Associates, St. Albans, VT) equipped with 
liquid dippers were used. Each chamber was located in a light- and sound-attenuating 
cabinet. The dimensions of the experimental chamber interior were 22 × 18 × 13 cm, with 
flooring consisting of metal rods placed 0.87 cm apart. A feeder trough was centered on one 
wall of the chamber. An infrared photocell detector was used to record head entries into the 
trough. Raising of the dipper inside the trough delivered a drop of evaporated milk. A 
retractable lever was mounted on the same wall as the feeder trough. A house light located 
on wall opposite to trough illuminated the chamber throughout all sessions.
Dipper and lever press training
Four weeks after AAV surgery, mice underwent operant training. Mice were weighed daily 
and food-restricted to 85–90% of baseline weight; water was available ad libitum. Mice 
were trained as previously described48. In the first training session, 20 dipper presentations 
were separated by a variable inter-trial interval (ITI) and ended after 20 rewards were earned 
or after 30 minutes, whichever occurred first. Mice reached criterion when head entries were 
made during 20 dipper presentations in one session. In the second training session, criterion 
was achieved when mice made head entries during 30 of 30 dipper presentations. Mice were 
trained to lever press on a continuous reinforcement (CRF) schedule. Levers were retracted 
after each reinforcer and were presented again after a variable ITI (average 30 seconds). The 
reward consisted of raising the dipper for 5 seconds, and the session ended when the mouse 
earned 60 reinforcements, or one hour elapsed, whichever occurred first. Sessions were 
repeated daily until mice achieved 60 reinforcements. Next, mice underwent fixed interval 
(FI) training wherein lever presses were reinforced until after a fixed interval (timed relative 
to the lever extension) had elapsed. Each reinforcement was followed by a variable inter-trial 
interval (average 30 seconds) during which the lever remained retracted, and then a new trial 
started, signaled by lever extension. Mice began with FI-4 s session and proceeded 
successively to longer interval sessions after earning ≥ 30 rewards in each session. The FI 
durations were 4, 8, 12, 16, and 24 seconds.
Progressive ratio (PR) task
Following FI schedules, mice were tested in a PR task, as previously described38, 49. Briefly, 
a reward was obtained after the mice made the required number of lever presses. The 
criterion was set at two lever presses for the first trial and the requirement doubled with each 
successive trial. The session ended after 2 hours or after 3 minutes had elapsed without a 
lever press. Breakpoint was defined as the last criterion successfully completed. Mean values 
from 4 daily PR sessions were analyzed. Investigators were blind to genotype of mice during 
the experiment and during data analysis. Mice were matched for age and sex.
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Statistics and data analysis
For dose-response curves, nonlinear regression analysis was performed using the sigmoidal 
dose-response function in GraphPad Prism. All values reported are mean ± standard error 
mean (S.E.M.). Statistical analyses were performed using Graphpad Prism.
Sample sizes for behavioral studies were determined by performing statistical power 
analyses based on effect sizes observed in preliminary data or on similar work in the 
literature. Histological verification of viral expression was used to exclude mice with 
misplaced injections from behavioral data analysis in a manner blinded to genotype. 
Statistical analyses were performed using Graphpad Prism. Data are expressed as mean ± 
S.E.M.. Paired and unpaired two-tailed Student’s t-tests were used to compare 2-group data, 
as appropriate. Multiple comparisons were evaluated by one-way or two-way ANOVA and 
Bonferroni’s post hoc test, when appropriate. Log-rank tests were used to analyze survival 
curves. All statistical tests met their respective assumptions. A pvalue of < 0.05 was 
considered statistically significant. Behavioral findings were successfully replicated with 
mice from different litters, ages, or sexes, and in several instances, across independent 
cohorts or related mouse strains.
Results
Development of an arrestin-biased D2R
Biased D2R mutants have been reported previously but their utility has been constrained by 
their incomplete bias towards either G proteins or arrestins41, 50 or diminished 
expression41, 51. The only reported arrestin-biased D2R mutant to date, 
D2R(A135R:M140D), enhanced locomotion when overexpressed in striatal D2R-expressing 
neurons of mice50, 52. However, this mutant was shown to be only partially biased toward 
arrestin recruitment50, which we confirmed using bioluminescence resonance energy 
transfer (BRET)-based G protein activation and arrestin recruitment assays in HEK293T 
cells. Under our assay conditions, maximal DA-induced G protein-dependent cAMP 
inhibition was impaired but still substantial (28 ± 2% of wildtype D2R (D2R-WT), n=3; 
Supplementary Figures 1A & C). The potency of DA was only slightly reduced compared 
to D2R-WT (~3-fold, Supplementary Figures 1A & D). Maximal DA-induced arrestin- 3 
recruitment to D2R(A135R:M140D) was relatively less impaired, but still considerably 
lower than D2R-WT (55 ± 3% of D2R-WT, n=3; Supplementary Figures 1B & C). Thus, 
although D2R(A135R:M140D) is partially arrestin-biased, it is unclear whether arrestin or 
residual G protein signaling (or both) downstream of D2R is responsible for enhanced 
locomotion in vivo.
To develop a more arrestin-biased D2R mutant with levels of arrestin recruitment more 
comparable to D2R-WT, we took advantage of a previously reported arrestin-biased, 
muscarinic acetylcholine receptor (mAChR)-based Designer Receptor Exclusively Activated 
by Designer Drugs (DREADD)53. A single point mutation of an arginine (R3.50 according to 
the Ballesteros- Weinstein GPCR numbering system54) to leucine in this receptor’s “DRY 
motif” resulted in strong arrestin bias53. The DRY motif is critically involved in receptor 
activation55 and is conserved across Family A GPCRs, including mAChRs and DARs. 
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Therefore, we mutated the DRY motif in D2R to DLY (D2R(R132L); Figures 1A & 1B), 
which greatly impaired DA-induced recruitment of the Gα subunit of Gi1 to the receptor (9 
± 5% of D2R-WT, n=5; Figure 1C)56. In contrast, R132L’s effect on DA-induced arrestin-3 
recruitment was less severe, though it still significantly reduced maximal arrestin-3 
recruitment (47 ± 8% of D2R-WT, n=6; two-tailed t-test, p<0.001) and potency (~16- fold 
lower compared to D2R-WT, n=6; two-tailed t-test, p<0.0001) (Figure 1D). Similar results 
were observed for arrestin-2 recruitment to D2R(R132L) (Supplementary Figure 2).
Even if D2R (R132L) preferentially recruits arrestin, its attenuated arrestin activity could 
still mask a role for arrestin-dependent processes in vivo. We hypothesized that combining 
R132L with mutations that increase receptor activity would enhance arrestin recruitment. 
The mutation of L3.41 to W (L123W in D2R) was shown previously to thermostabilize 
Family A GPCRs and facilitate their crystallization57, e.g., this mutation is present in the 
crystal structure of a close homolog of D2R, DA D3R58. Interestingly, DA was significantly 
more potent at D2R(L123W) (Figures 1A & 1B) compared to D2R-WT in assays 
measuring the recruitment of Gαi1 (~4-fold; two-tailed t-test; p<0.01; Figure 1C), 
arrestin-2 (~14-fold; two-tailed t-test, p<0.01; Supplementary Figure 2) and arrestin-3 
(~14-fold; two-tailed t-test; p<0.0001; Figure 1D), suggesting that L123W enhances the 
affinity of the receptor for DA and/or the ability of the receptor to populate an active 
conformational state when bound to agonist.
As hypothesized, combining R132L and L123W created a mutant, D2R(L123W:R132L) 
(Figures 1A & B), that was capable of robustly recruiting arrestin-3 (100 ± 7% of D2R-WT, 
n=3; Figure 1D) and arrestin-2 (132 ± 9% of D2R-WT, n=3; Supplementary Figure 2). 
Consistent with its effect on D2R-WT, the L123W mutation combined with R132L 
enhanced the potency of DA by ~4-fold relative to that in R132L in both the arrestin-2 and 
−3 recruitment assays. When compared to D2R WT, D2R(L123W:R132L) was still ~2- to 
~4-fold less sensitive to DA for the recruitment of arrestin-2 and −3, respectively. 
Remarkably, D2R(L123W:R132L) was devoid of detectable Gαi1 activity (n=3; Figure 
1C). D2R(L123W:R132L) expressed at the plasma membrane of HEK293T cells at 75 ± 8% 
(n=6) of D2R-WT (Supplementary Figure S3 & Figure 1E). Furthermore, L123W:R132L 
conferred arrestin-bias to both the short (Figure 1) and long isoforms of D2R 
(Supplementary Figure 4).
Of note, D2R has been reported to couple more potently to Go than Gi isoforms59, 60, and it 
has been inferred based on knockout data that Go is a critical mediator of D2R activity in 
vivo61, 62. Thus, we carried out a BRET-based assay comparing the ability of each Gαi/o/z 
isoform to support DA-induced recruitment of the G protein subunit Gγ to D2R-WT or 
D2R(L123W:R132L). Consistent with our results for Gαi1 recruitment (Figure 1C), 
D2R(L123W:R132L) failed to recruit the Gγ subunit of Gi1, Gi2, Gi3, Goa, or Gz (Figure 
1F).
We next tested whether G protein or arrestin recruitment to D2R-WT and its mutants 
correlated with the engagement of processes downstream of these signaling proteins. We 
first measured inhibition of cyclic AMP (cAMP) accumulation by endogenous Gi/o in 
HEK293T cells. Whereas DA robustly inhibited cAMP accumulation in cells expressing 
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D2R(L123W) (107 ± 3% of D2R-WT, n=3), it had essentially no effect in those expressing 
D2R(R132L) and D2R(L123W:R132L) (1 ± 1% and 3 ± 3% of D2R-WT, respectively, n=3; 
Figure 1G). Similar effects were observed for D2R(L123W:R132L) even in cells 
overexpressing Gi1 (3 ± 5% of D2R-WT; n=4; Supplementary Figure 5). Overall, these 
results are consistent with the impaired G protein recruitment to D2R(R132L) and 
D2R(L123W:R132L) (Figure 1C).
We showed previously that arrestin-mediated internalization of D2R requires an interaction 
between the receptor and the β2-adaptin subunit of clathrin-associated adaptor protein-2 
(AP- 2)41. In a BRET-based assay that we developed previously41, DA dose-dependently 
enhanced the interaction between AP-2 and D2R-WT (Supplementary Figure 6)41. There 
was no significant difference in the DA-induced interaction between AP-2 and D2R-WT or 
D2R(L123W:R132L) (twotailed t-test, p=0.98). Consistent with this observation, there was 
no significant difference in arrestin-dependent, DA-induced internalization of D2R-WT and 
D2R(L123W:R132L) (two-tailed t-test, p=0.49; Figure 1H). These results indicate that 
D2R(L123W:R132L) recruits arrestin that can then bind accessory proteins and facilitate 
processes downstream of receptor activation.
It is conceivable that D2R(L123W:R132L) only appears biased towards arrestins because its 
basal (constitutive) activation of G proteins is extremely high, and thus the receptor is 
incapable of further activating these signaling proteins in response to DA. We used the D2R 
inverse agonist sulpiride63 to assess the constitutive G protein activity of D2R-WT, 
D2R(L123W:R132L) or D2R(E339A:T343R), a reported constitutively active mutant 
(CAM) of D2R64, in the cAMP assay. Sulpiride robustly reversed constitutive inhibition of 
cAMP accumulation by the CAM, and to a lesser degree that by D2R-WT (Supplementary 
Figure 7). However, it had no effect on cells expressing D2R(L123W:R132L) or mock 
transfected cells not expressing receptor (Supplementary Figure 7), indicating that this 
mutant does not constitutively activate G proteins. Overall, these results indicate that G 
protein activation by D2R(L123W:R132L) is disrupted whereas arrestin recruitment is 
intact.
Bias is maintained in the brain
To express the arrestin-biased D2R(L123W:R132L) mutant (henceforth called D2R-ARB) 
in vivo, we generated a Cre recombinase (Cre)-dependent AAV encoding a double-inverted 
open reading frame (DIO) containing this mutant followed by an internal ribosome entry site 
(IRES) and the YFP variant mVenus under the control of the synapsin promoter I (Synl; 
Figure 2A). We selectively expressed this receptor in iMSNs by injecting AAV in the NAc 
of adult Drd2−/−A2A-Cre mice (Figure 2B). We also injected AAVs containing EGFP or 
D2R-WT. Four weeks following injection of the AAVs, we observed EGFP or mVenus 
expression in the NAc (Figure 2C). The presence of D2R-WT or D2R-ARB was also 
verified by D2R immunofluorescence (Figure 2C). Comparable D2R dendritic-like 
immunoreactivity was observed in mice infected with D2R-WT and D2R-ARB AAVs 
(Figure 2C), consistent with their similar levels of expression in HEK293T cells (Figure 
1E).
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By expressing D2R-ARB in a D2R-KO background, we could assess its signaling properties 
independently of native D2R-mediated G protein signaling and thus determine whether the 
bias observed in heterologous cells is maintained ex vivo in the iMSNs. We measured G 
protein activity using a GTPγS incorporation assay in dorsal striatal homogenates46 (see 
Methods). Experiments were performed with the selective D2-like receptor agonist 
quinpirole to avoid activation of D1- like receptors and because quinpirole has similar 
efficacy as DA at both G protein activation (Supplementary Figure 8) and arrestin 
recruitment65. Not surprisingly, quinpirole induced robust G protein activation in 
heterozygotic D2R-KO mice (Drd2+/−A2A-Cre), but had no effect in homozygous D2R-KO 
(Drd2−/−A2A-Cre) mice infected with EGFP (Figure 2D). Whereas the selective restoration 
of D2R-WT in NAc-iMSNs rescued robust G protein activation in the D2RKO background, 
D2R-ARB had no effect (Figure 2D), consistent with its inability to activate G proteins in 
HEK293T cells (Figures 1C & F). To verify that AAV-mediated D2R overexpression did 
not affect the function of other Gi/O/z-coupled receptors, we activated cannabinoid receptors 
(CBRs) with the agonist CP55,94066. There was no significant difference in the ability of 
this ligand to activate G proteins downstream of CBRs in any of the groups, indicating that 
Gi/o/z activation was not generally disrupted (Figure 2E). Furthermore, baseline GTPγS 
was not significantly different between any of the groups (Figure 2F), suggesting that 
overexpression of EGFP, D2RWT, or D2R-ARB did not result in compensatory changes in 
basal G protein activity.
Selective restoration of D2R-mediated arrestin recruitment in accumbens-iMSNs reverses 
blunted locomotion in D2R-deficient mice
To address whether D2R-mediated G protein signaling is essential for D2R-mediated 
locomotion, we directed the expression of EGFP, D2R-WT or D2R-ARB to NAc-iMSNs of 
mice that lack native D2R (Drd2−/−A2A-Cre mice) using Cre-dependent AAVs, as described 
above (Figures 2A-C).
A number of studies have shown that ablation of the D2R gene in mice results in 
hypolocomotion as well as a blunted locomotor response to an acute administration of 
cocaine67, 68, which enhances DAR signaling by preventing the uptake of DA by its 
transporter (DAT)68. We tested whether D2R-WT or D2R-ARB is sufficient to reverse these 
phenotypes when expressed selectively in NAc-iMSNs of Drd2−/−A2A-Cre mice. 
Locomotor activity was assessed across three consecutive days for 90 minutes after 
intraperitoneal injections of either saline on days one and two or cocaine (15 mg/kg) on day 
three (Figure 3).
There was no significant difference in locomotor activity between EGFP, D2R-WT and 
D2RARB-virus-injected mice on day one (one-way ANOVA, F(2,31)=2.11, p=0.14, n=11–12 
mice in each group; Figure 3A). However, on day two, locomotor activity was significantly 
higher in D2R-WT and D2R-ARB virus-injected mice compared to EGFP mice (one-way 
ANOVA, F(2,31)=5.23, p<0.05, Bonferroni, t=2.97 and 2.61, respectively, p<0.05, n=11–12 
mice in each group; Figure 3B). Moreover, there was no significant difference in locomotor 
activity between D2R-WT and D2R-ARB virus-injected mice (one-way ANOVA, 
Bonferroni, t=0.43, p>0.05; Figure 3B).
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Both D2R-WT and D2R-ARB mice exhibited a robust increase in locomotor activity in 
response to administration of cocaine that was significantly different from that for EGFP 
mice (one-way ANOVA, F(2,31)=7.85, p=0.002, Bonferroni, t=3.54 and 3.34, respectively, 
p<0.05, n=11–12 mice in each group; Figures 3C). Moreover, there was no difference in the 
total distance traveled between D2R-WT and D2R-ARB mice in response to cocaine (one-
way ANOVA, Bonferroni, t=0.28; Figure 3C). These results indicate the restoration of D2R-
mediated arrestin recruitment in NAc-iMSNs, in the apparent absence of D2R-mediated G 
protein signaling, is sufficient to reverse basal hypolocomotion in D2R-KO mice. Moreover, 
with respect to the role of D2R, arrestin recruitment in iMSNs is sufficient to mediate the 
full psycholocomotor actions of cocaine.
Upregulated D2R-mediated arrestin recruitment enhances locomotion but not motivation
We recently upregulated D2R-WT in D2R-expressing NAc-iMSNs of D2-Cre mice that 
express native D2R-WT and observed a robust increase in basal locomotion in an open field 
assay as well as increased motivation in a progressive ratio task measuring motivation38, 48. 
Our recent mechanistic analysis suggests that D2R in iMSNs promotes motivation mainly by 
weakening canonical iMSN output to the ventral pallidum (VP) through their actions at the 
iMSN terminals48. This effect, by analogy with presynaptic D2-autoreceptor function in 
dopamine neurons, is most likely to be G protein-mediated69–71. Therefore, we hypothesized 
that the D2R-mediated enhancement of motivation would be dependent on G protein 
signaling at iMSN terminals, and thus compared the ability of the D2R-ARB to regulate 
these D2R-mediated behaviors with that of D2R-WT and the EGFP control when the 
receptors were upregulated in D2R wild-type mice.
We selectively overexpressed D2R-ARB as well as EGFP or D2R-WT in NAc-iMSNs of 
D2- Cre mice using the AAVs described above (Figure 4A). Four weeks after injection of 
the AAVs, we observed EGFP or mVenus expression in the NAc, as well as comparable 
levels of overexpressed D2R-WT or D2R-ARB (Figure 4B).
In agreement with our previous work38, basal locomotion was significantly higher in mice 
overexpressing D2R-WT than in those expressing EGFP (one-way ANOVA, F(2,24) = 9.06, 
p<0.05, Bonferroni, t=3.47, p<0.05, n=8–10 mice in each group; Figure 4C, 4D & 
Supplementary Figure 9A). Interestingly, overexpression of D2R-ARB significantly 
enhanced locomotion relative to the EGFP control (Bonferroni t=3.78, p<0.05) to the same 
level as D2R-WT overexpression (Figure 4D). Thus, the overexpression of a receptor 
capable of recruiting arrestins but not G proteins is sufficient to enhance basal locomotion, 
just as it can rescue basal locomotion in the D2R-KO background (Figure 3).
Using the same mice, we next investigated whether the D2R-ARB acts similarly to D2R-WT 
in the regulation of motivation. We showed previously that upregulation of D2R-WT in 
NAc-iMSNs increases motivation but does not alter consummatory behavior48, 49. Using a 
progressive ratio (PR) lever pressing task, we measured the willingness to expend effort to 
obtain a food reward by D2-Cre mice expressing EGFP, D2R-WT or D2R-ARB. Consistent 
with our previous findings, lever pressing (Figure 5A) and breakpoint (Figure 5B) were 
significantly higher in mice expressing D2R-WT than those expressing the EGFP control 
(one-way ANOVA, lever pressing: F(2,23)=11.66, p<0.05, Bonferroni, t =4.57, p<0.05; 
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breakpoint: F(2,23)=10.39, p<0.05, Bonferroni, t=4.14, p<0.05). Remarkably, lever pressing 
and breakpoint were not significantly different between mice expressing EGFP and D2R-
ARB (lever pressing: Bonferroni, t=0.63, p>0.05; breakpoint: Bonferroni, t=0.14, p>0.05, 
Figure 5A & 5B). A survival curve analysis of the percentage of mice that continued to 
respond as a function of time detected an overall group effect (Log-rank test; χ2=13.33, 
p<0.005), and pairwise log-rank tests comparing groups indicated that a greater number of 
D2R-ARB mice lasted significantly less time in the PR session than D2RWT mice but more 
time than EGFP mice (EGFP vs D2R-WT, χ2=12.54, p<0.0005; D2R-WT vs. D2R-ARB, 
χ2=7.407, p=0.0065; EGFP vs. D2R-ARB, χ2=2.222, p=0.1361; Figure 5C). Since a single 
press of the lever during a three-minute time period will extend the PR session, a very small 
increase in lever presses can extend session time without a significant increase in total lever 
presses or rewards received. Press rate, was unaltered by expression of either D2R-WT or 
D2RARB (one-way ANOVA, F(2, 23)=1.42, p=0.26; Figure 5D). Thus, these data indicate 
that overexpression of a D2R capable of selectively recruiting arrestin enhances locomotor 
activity, but is not sufficient to increase responding in a task measuring incentive motivation.
Discussion
Our understanding of the mechanisms by which D2R regulates diverse physiological 
processes has been limited by the nature of available genetic35, 50 and pharmacological 
tools31. While optogenetic and chemogenetic approaches are uncovering details regarding 
the circuitry underlying distinct behaviors72–75, very little is known about the roles in DA-
mediated behaviors of distinct D2R-mediated signaling pathways in specific cell types. 
Using a novel arrestin-biased D2R mutant (L123W:R132L), termed D2R-ARB, we have 
shown in global D2R-KO mice that D2R-mediated arrestin recruitment in NAc-iMSNs 
enhances basal locomotion and supports cocaine-induced hyperlocomotion to the same 
extent as D2R-WT. These results indicate that arrestin recruitment to D2R in iMSNs can 
facilitate locomotor activity in the apparent absence of D2R-mediated G protein signaling. 
The D2R has also been shown to interact with a number of other proteins76, and it is 
conceivable that the mutations in the D2R-ARB also disrupt other as yet unidentified 
functions.
The effects of D2R-ARB on locomotion are consistent with previous work showing that a 
global loss of arrestin-3 attenuates psychostimulant-induced locomotion35. These results, 
however, appear inconsistent with results showing that biased-D2R ligands, which 
selectively promote arrestin signaling, inhibit psychostimulant-induced locomotion31. This 
inconsistency may be due to the partial agonism of these first-generation biased ligands, 
which can confound the impact of bias by acting as partial antagonists to limit the ability of 
endogenously released DA to fully activate the arrestin pathway. Recent work with an 
engineered, partially arrestin-biased D2R showed that arrestin recruitment enhanced basal 
locomotion to only about half the level produced by D2R-WT52. This stands in contrast to 
our results and reflects the complexity of engineering biased receptors; indeed, consistent 
with the published behavioral results, we find that this receptor can only recruit arrestin to 
about 50% of the level of D2R-WT (Supplementary Figures 1B & C). In contrast, our 
arrestin-biased mutant, D2R-ARB, mediates full arrestin recruitment (Figure 1D), normal 
internalization (Figure 1G) and fully phenocopies the basal hyperlocomotor effects of D2R-
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WT (Figures 4C & D), even in a D2R-KO background (Figure 3). Furthermore, in the 
global D2R-KO background, cocaine enhanced locomotion to the same extent in mice 
expressing D2R-WT or D2R-ARB (Figures 3B & D), suggesting that acute D2R-mediated 
arrestin recruitment is sufficient to facilitate locomotion, whereas D2R-mediated G protein 
activation does not appear to be necessary. While we cannot rule out a role for some residual 
G protein activity in our D2R-ARB, any such activity is not detectable in the GTPγS assay 
(Figure 2D) or the G protein recruitment assays (Figure 1 and Supplementary Figure 4).
Our findings are consistent with an important role for arrestin-mediated signaling 
downstream of D2R. Most likely this signaling is mediated by arrestin scaffolding of Akt 
and PP2A, which decreases Akt activity, thereby reducing GSK3β phosphorylation and 
enhancing GSK3β activity35, 77. Indeed, an increasing body of work implicates GSK3β 
activation in DA-mediated locomotion77. Moreover, cocaine78- and amphetamine79-induced 
locomotion is inhibited by the specific GSK3β inhibitor SB 216763 as well as by 
heterologous knockout of GSK3β79. The target or targets of GSK3β phosphorylation that 
lead to enhanced locomotion are unknown, but some evidence points to GSK3β-mediated 
regulation of NMDA and AMPA receptors80, 81, which merits further study as a potential 
mechanism for how arrestin recruitment can affect locomotor activity.
In contrast to locomotion, incentive motivation was enhanced by the upregulation of D2R-
WT but not by D2R-ARB. To our knowledge, this is the first study to dissociate between the 
mechanisms that underlie D2R-dependent locomotion and incentive motivation. Enhanced 
PR performance can result from enhanced arousal and an attendant enhancement in the 
activational component of motivation. In addition, enhanced PR performance can also be 
due to an enhancement in the directional component of motivation driven by the reward 
value. Our results suggest different mechanisms for each of these contributions. While the 
D2R-ARB did not produce a significant increase in lever presses or rewards, consistent with 
its inability to enhance incentive motivation, D2R-ARB did significantly extend survival in 
the PR protocol to a level intermediate between control and D2R-WT (Figure 5C). The 
survival analysis is a measure that is highly sensitive to the activational component of 
motivation, since a single press of the lever during a three-minute time period extends the 
PR session. Thus, behavioral activation, through a very small increase in lever presses, can 
extend session time without a significant increase in total lever presses or rewards received. 
This demonstrates that the PR protocol captures both the activational and goal-directed 
aspects of incentive motivation, which we have now disentangled with our pathway-selective 
receptor construct. Importantly, our results offer the possibility that therapeutic approaches 
that target distinct D2R-mediated signaling pathways in a cell typespecific manner may 
avoid adverse effects associated with conventional D2R-targeting medications by selectively 
engaging only a subset of D2R-mediated behavioral processes.
It is indeed remarkable that the activation of different signaling pathways in the same 
neurons can result in enhancement of distinct behaviors. Even though the receptors are 
expressed in the same population of iMSNs, we do not yet know whether a distinct 
subpopulation of neurons within the iMSN population mediates the different behaviors 
through different effector mechanisms, or whether activation of the different pathways in the 
same neurons can produce these divergent behaviors. Using slice electrophysiology paired 
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with optogenetics, we have recently shown that D2R upregulation attenuates inhibitory 
transmission of iMSN output to the ventral pallidum (VP) 48. In vivo recordings confirmed 
the reduction in indirect pathway inhibitory transmission to the VP, and localized 
pharmacogenetic inhibition of iMSN terminals within the VP was sufficient to enhance 
motivation. These results suggest that D2R in iMSNs promotes incentive motivation mainly 
by weakening their canonical output to the VP through their actions at the iMSN 
terminals48.
In dopaminergic neurons, presynaptic D2-autoreceptors are thought to inhibit dopamine 
release from axon terminals via Gβγ-mediated inhibition of voltage-gated calcium channels 
and activation of Kv1.2 potassium channels69–71. Likewise, slice physiology studies have 
shown that pharmacological activation of D2R reduces inhibitory transmission at 
striatopallidal synapses82–85. These data suggest that D2R-mediated G protein activation is 
essential to inhibit iMSN terminals in the VP to enhance incentive motivation, in accordance 
with our findings that D2R-ARB does not enhance motivation. Analogous studies with a G 
protein-biased D2R mutant will be critical for providing insight into the roles of G protein 
signaling on incentive motivation and other D2Rdependent behaviors.
Of note, our studies have focused on the role of D2R-mediated signaling in the NAc. We 
previously have shown that inhibition of indirect pathway function produced by activating 
the Gi/arrestin coupled DREADD receptor hM4D enhances locomotion both in the dorsal 
and ventral striatum74. Thus, D2R upregulation in the dorsal striatum is also likely to 
enhance activity. It is conceivable, however, that the underlying signaling mechanisms may 
differ due to differences between the role of G protein-dependent and -independent signaling 
in iMSNs of the dorsal versus the ventral striatum41, 50, 51, and this will require further 
investigation. The expression of biased D2Rs in D2R in neuronal populations other than the 
NAc may provide further insight into the role of D2R, not only for the regulation of 
locomotion and motivation, but for other DAdependent behaviors as well. Such studies may 
ultimately shed light on the D2R populations and signaling pathways that must be targeted 
to maximize clinical efficacy and reduce adverse side effects.
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Figure 1. An extremely arrestin-biased D2R mutant receptor, D2R(L123W:R132L).
A) Snake-plot representation of D2R highlighting mutated residues R132 (red) to L and 
L123 (blue) to W in transmembrane segment 3 (TM3).
B) Ribbon representation of D2R co-crystallized with the D2-like receptor antagonist 
risperidone. Risperidone (orange) is shown bound to the DA-binding orthosteric binding site 
(OBS) of the receptor, which is formed by the TM bundle and lies above the mutated 
residues R132 (red) and L123 (blue).
C) Schematic representation of a bioluminescence resonance energy transfer (BRET)-based 
assay that measures agonist-induced recruitment of Gαi1 (α) fused to mVenus (V) in its α-
helical domain to D2R fused to Renilla luciferase 8 (RL) at its C-terminus (inset). Gαi1-
recruitment to D2R-WT, D2R(R132L), D2R(L123W), or D2R(L123W:R132L) in response 
to increasing concentrations of DA. Dose-response curves are representative of independent 
experiments (n= 6, 6, 3, and 3, respectively) performed in triplicate.
D) Schematic representation of a BRET-based assay that measures agonist-induced 
recruitment of arrestin-3 (AR) fused at its N-terminus to mVenus (V) to D2R-Rluc8 (inset). 
Arrestin-3- recruitment to D2R-WT, D2R(R132L), D2R(L123W), or D2R(L123W:R132L) 
in response to increasing concentrations of DA (refer to Figure 1C for figure legend). Dose-
response curves are representative of independent experiments (n= 6, 6, 3, and 3, 
respectively) performed in triplicate.
E) Surface expression of D2R(R132L), D2R(L123W) and D2R(L123W:R132L) in 
HEK293T cells as a percentage of D2R-WT. Bars represent the average of six to seven 
independent experiments.
F) Gγ-mVenus recruitment to D2R-WT and D2R(L123W:R132L) with co-expression of 
pertussis toxin insensitive variants of human Gαi1–3 or GαoA or wildtype human Gαz in 
response to 100 μΜ DA. Cells were treated with 100 ng/mL pertussis toxin prior to 
measurement of response. Responses represent a change in BRET normalized to that of 100 
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μΜ DA at the D2R-WT with coexpression of Gαi1. Bars represent the average of four to 
five independent experiments.
G) Gi/o/z-mediated inhibition of forskolin (30 μM)-induced cyclic AMP accumulation 
(cAMPi) for D2R-WT, D2R(R132L), D2R(L123W), and D2R(L123W:R132L) in response 
to increasing concentrations of DA (refer to Figure 1C for figure legend). Dose-response 
curves are representative of three independent experiments performed in triplicate.
H) The percentage of D2R-WT, D2R(R132L), D2R(L123W), and D2R(L123W:R132L) that 
internalizes in response to DA (10 μM) after one hour. Bars represent the average of four to 
six independent experiments.
The short isoform of D2R (D2Rs) was used for all experiments with the exception of the 
Gγ- mVenus recruitment assay. Error bars represent S.E.M.
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Figure 2. Arrestin bias downstream of D2R in iMSNs of the NAc.
A) Schematic representation of AAV1/2-hSyn1-DIO-SF-D2R-IRES-mVenus. The 
expression cassette is oriented in the forward direction in the presence of Cre-recombinase, 
which recognizes flox sites (black and white arrows) (top). The AAV was injected into the 
NAc of Drd2−/−A2A-Cre mice (bottom).
B) Schematic of striatal neurons from mice lacking native D2Rs. D2R-WT or D2R-ARB 
(red ovals) was selectively expressed in NAc-iMSNs by injecting Cre-dependent AAVs into 
the ventral striatum of Drd2−/−A2A-Cre mice.
C) AAV-induced expression of EGFP, D2R-WT, or D2R-ARB in NAc four weeks after 
injection. Shown are D2R immunoreactivity (left) and EGFP (top right) or mVenus (middle, 
bottom right) fluorescence. Mean D2R immunofluorescence intensity analysis showed 
similar D2R levels in both D2R groups (D2R-WT: 1.70 ± 0.07 A.U., n=4 mice; D2R-ARB: 
1.83 ± 0.07 A.U., n=5 mice; p = 0.21). Scale bar equals 100 μm.
(D) Quinpirole- or (E) CP55,940-induced 35S-GTPγS binding in dorsal striatal membranes 
prepared from Drd2+/-A2A-Cre (D2R-HET) or Drd2−/−mice. Drd2−/−A2A-Cre mice were 
injected with Cre-dependent AAVs encoding EGFP, D2R-WT, or D2R-ARB. Dose-response 
curves were fit globally from three independent experiments performed in duplicate. Dose-
response curves were normalized to a vehicle control.
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F) Baseline 35S-GTPγS incorporation did not differ between the samples in assays 
performed in parallel.
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Figure 3. Selective expression of D2R-ARB in iMSNs of the NAc reverses blunted locomotor 
responses in D2R-knockout mice.
Time course of distance traveled (cm) by Drd2−/−A2A-Cre mice expressing EGFP, D2R-
WT, or D2R-ARB 90 minutes following the injection of saline on day 1 (A, top), saline on 
day 2 (B, top), and cocaine (15 mg/kg) on day 3 (C, top). Total distance traveled by EGFP, 
D2R-WT, or D2RARB mice in an open field over 90 minutes after the injection of saline on 
day 1 (A, bottom), saline on day 2 (B, bottom), and cocaine on day 3 (C, bottom).
One-way ANOVA, Bonferroni. *p<0.05, **p<0.01, EGFP (n=11), D2R-WT (n=11), and 
D2R-ARB (n=12), respectively. Error bars represent S.E.M.
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Figure 4. Overexpression of an arrestin-biased D2R in the NAc of mice enhances locomotion.
A) Schematic depicting neurons in the striatum that express native D2R (blue ovals). These 
include iMSNs, cholinergic interneurons (ChIs) as well as dopaminergic (DA) and 
glutamatergic (GIu) neurons, which express D2Rs at their terminals. D2R-WT or D2R-ARB 
(red ovals) were upregulated selectively in postsynaptic D2R-expressing iMSNs of D2-Cre 
mice.
B) AAV-induced expression of EGFP, D2R-WT, or D2-ARB in NAc four weeks following 
injection. Shown are D2R immunoreactivity (left), EGFP (top right), or mVenus (middle, 
bottom right) fluorescence. Mean D2R immunofluorescence intensity analysis showed 
similar D2R upregulation in both D2R groups (D2R-WT: 5.70 ± 0.30 A.U., n=3 mice; D2R-
ARB: 5.95 ± 0.77 A.U., n=3 mice; p = 0.77). Scale bar equals 100 μm.
C, D) Distance traveled (cm) over 90 minutes in an open field by D2-Cre mice expressing 
EGFP, D2R-WT, or D2R-ARB.
One-way ANOVA, Bonferroni. **p<0.01, EGFP (n=10), D2R-WT (n=9), and D2R-ARB 
(n=8), respectively. Error bars represent S.E.M.
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Figure 5. Overexpression of an arrestin-biased D2R in the NAc of mice does not enhance 
motivation.
A) Average lever presses in a progressive ratio (PR)-task by D2-Cre mice expressing EGFP, 
D2R-WT, or D2R-ARB and (B) breakpoint were significantly increased in D2R-WT relative 
to D2R-ARB or EGFP. One-way ANOVA, Bonferroni. *p<0.05 and ***p<0.001, EGFP 
(n=10), D2RWT (n=9), and D2R-ARB (n=9), respectively.
C) Effect of overexpressing D2R-WT or D2R-ARB on PR session duration. Kaplan-Meier 
survival function showing the percentage of mice that continue to respond on the PR 
schedule as a function of session time. Average data of four PR sessions are shown. Log-
rank test showed overall group effect (χ2=13.33, p<0.005), and pairwise log-rank tests 
comparing between groups indicated that D2R-ARB (n=8) and EGFP (n=10) mice lasted 
significantly less time in the PR session than D2R-WT (n = 8) mice (EGFP vs D2R-WT, 
χ2=12.54, p<0.0005; D2R-WT vs. D2RARB, χ2=7.407, p=0.0065; EGFP vs. D2R-ARB, 
χ2=2.222, p=0.1361).
D) Press rate, plotted here as a function of the ratio requirement, was not altered. One-way 
ANOVA, p=0.26, EGFP (n=10), D2R-WT (n=9), and D2R-ARB (n=9), respectively. Error 
bars represent S.E.M.
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